Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity in clinical practice

Abstract

Background The POSE-2 procedure shortens and narrows the stomach using multiple full-thickness plications in the gastric body. We studied the efficacy and safety of POSE-2 for obesity at 1 year in a real-world setting.

Methods We reviewed the records of 75 patients who underwent POSE-2 at our unit. The primary outcome was percentage total body weight loss (%TBWL) at 1 year. Secondary outcomes were safety and durability. We used linear mixed model analysis.

Results 46 patients completed 1 year. Mean age and body mass index (BMI) were 49.3 years (standard deviation [SD] 10.2) and 38.2 kg/m² (SD 6.6), respectively. Technical success rate was 98.7 % (n = 74). Mean TBWL, %TBWL, and BMI decline at 1 year were 20 kg (SD 12.7), 17.8 % (SD 9.5), 7 kg/m² (SD 4.3). Adverse events occurred in four patients. The median length of stay was 1 day. Endoscopy at 1 year in 15 patients showed intact sutures and a reduction in gastric length compared with baseline (26.9 cm [SD 5.3] vs. 35.7 cm [SD 3.5]; P < 0.001).

Conclusion POSE-2 induced significant weight loss at 1 year. It appears to be safe, durable, and required only a short hospital stay.

^* These authors contributed equally to this work.

Publication History

Received: 17 August 2020

Accepted: 27 November 2020

Accepted Manuscript online:
27 November 2020

Article published online:
21 January 2021

• References

• 1 Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013; 23: 427-436
• 2 Mohan BP, Asokkumar R, Khan SR. et al. Outcomes of endoscopic sleeve gastroplasty; how does it compare to laparoscopic sleeve gastrectomy? A systematic review and meta-analysis. Endosc Int Open 2020; 8: E558-E565
• 3 Lopez-Nava G, Asokkumar R, Bautista I. et al. Endoscopic sleeve gastroplasty (ESG), laparoscopic sleeve gastrectomy (LSG), and laparoscopic greater curve plication (LGCP): do they differ at 2-years?. Endoscopy 2020;
• 4 Lopez-Nava G, Negi A, Bautista-Castaño I. et al. Gut and metabolic hormones changes after endoscopic sleeve gastroplasty (ESG) vs. laparoscopic sleeve gastrectomy (LSG). Obes Surg 2020; 30: 2642-2651
• 5 López-Nava G, Bautista-Castaño I, Jimenez A. et al. The primary obesity surgery endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis 2015; 11: 861-865
• 6 Sullivan S, Swain JM, Woodman G. et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial. Obesity (Silver Spring) 2017; 25: 294-301
• 7 Jirapinyo P, Thompson CC. Endoscopic gastric body plication for the treatment of obesity: technical success and safety of a novel technique (with video). Gastrointest Endosc 2020; 91: 1388-1394
• 8 Lopez Nava G, Turro A, Maselli D. et al. Primary obesity surgery endoluminal-2 (POSE2): an international multicenter prospective trial. Gastrointest Endosc 2020; 91: AB60
• 9 Lopez-Nava G, Asokkumar R, Turró Arau R. et al. Modified primary obesity surgery endoluminal (POSE-2) procedure for the treatment of obesity. VideoGIE 2020; 5: 91-93
• 10 Aranceta BartrinaJ, Arija ValV. Grupo Colaborativo de la Sociedad Española de Nutrición Comunitaria (SENC). et al. Dietary guidelines for the Spanish population (SENC, December 2016); the new graphic icon of healthy nutrition. Nutr Hosp 2016; 33: 1-48
• 11 García-García ML, Martín-Lorenzo JG, Lirón-Ruiz R. et al. Perioperative complications following bariatric surgery according to the Clavien-Dindo classification. Score validation, literature review and results in a single-centre series. Surg Obes Relat Dis 2017; 13: 1555-1561
• 12 Abu Dayyeh BK, Kumar N. ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee, ASGE Bariatric Endoscopy Task Force. et al. systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015; 82: 425-438.e5
• 13 Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep 2017; 6: 187-194
• 14 Lopez-Nava G, Asokkumar R, Negi A. et al. Re-suturing after primary endoscopic sleeve gastroplasty (ESG) for obesity. Surg Endosc 2020;
• 15 Cheskin LJ, Hill C, Adam A. et al. Endoscopic sleeve gastroplasty versus high-intensity diet and lifestyle therapy: a case-matched study. Gastrointest Endosc 2020; 91: 342-349.e1